US OptionsDetailed Quotes
ACAD241220P15000
- 0.25
- 0.000.00%
15min DelayClose Nov 29 13:00 ET
0.00High0.00Low
0.25Open0.25Pre Close0 Volume467 Open Interest15.00Strike Price0.00Turnover57.64%IV9.62%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type-0.2436Delta0.1387Gamma46.63Leverage Ratio-0.0165Theta-0.0023Rho-11.36Eff Leverage0.0123Vega
ACADIA Pharmaceuticals Stock Discussion
Sign in to post a comment
$HWH International (HWH.US)$ 13D 88.9%. China stock. Low float. SI 214%✅
$Infobird Software (IFBD.US)$ Completed $40M acquisition. China stock. Low float. 0 shares LTB✅
$Ocean Power Technologies (OPTT.US)$ Form 4 insider buying. 0 shares LTB✅
$T Stamp (IDAI.US)$ Ran today. Up after hours. Possible catalyst. Low float. 0 shares LTB✅
$Syra Health (SYRA.US)$ Recent Form 4s multiple insider loading. Low fl...
$Infobird Software (IFBD.US)$ Completed $40M acquisition. China stock. Low float. 0 shares LTB✅
$Ocean Power Technologies (OPTT.US)$ Form 4 insider buying. 0 shares LTB✅
$T Stamp (IDAI.US)$ Ran today. Up after hours. Possible catalyst. Low float. 0 shares LTB✅
$Syra Health (SYRA.US)$ Recent Form 4s multiple insider loading. Low fl...
36
20
$ACADIA Pharmaceuticals (ACAD.US)$
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
Acadia Pharmaceuticals (NASDAQ: ACAD) has secured an exclusive worldwide license agreement with Saniona for SAN711, a first-in-class GABAA-α3 positive allosteric modulator.
The company plans to develop SAN711 for essential tremor treatment, with Phase 2 studies expected to begin in 2026. Under the agreement, Saniona will receive a $28 million upfront payment plus potential ...
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
Acadia Pharmaceuticals (NASDAQ: ACAD) has secured an exclusive worldwide license agreement with Saniona for SAN711, a first-in-class GABAA-α3 positive allosteric modulator.
The company plans to develop SAN711 for essential tremor treatment, with Phase 2 studies expected to begin in 2026. Under the agreement, Saniona will receive a $28 million upfront payment plus potential ...
$ACADIA Pharmaceuticals (ACAD.US)$ Reuters· 1 min ago
ACADIA Pharmaceuticals Inc - Saniona to Receive $28 Million Upfront Plus up to $582 Million in Milestones with exclusive licensing agreement with Saniona for San711
ACADIA Pharmaceuticals Inc - Saniona to Receive $28 Million Upfront Plus up to $582 Million in Milestones with exclusive licensing agreement with Saniona for San711
1
$ACADIA Pharmaceuticals (ACAD.US)$ Reuters· just
ACADIA Pharmaceuticals Enters Into an Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million
ACADIA Pharmaceuticals Enters Into an Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...
10
Analysts have high confidence in ACADIA Pharmaceuticals, predicting an average annual growth rate of 42%. The company's lack of debt reduces concerns around repayments and makes it a less risky investment.
1
Several companies were in the spotlight due to various developments:
Oracle ( $Oracle (ORCL.US)$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $ACADIA Pharmaceuticals (ACAD.US)$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts (MTN.US)$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$Asana (ASAN.US)$ Asana rep...
Oracle ( $Oracle (ORCL.US)$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $ACADIA Pharmaceuticals (ACAD.US)$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts (MTN.US)$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$Asana (ASAN.US)$ Asana rep...
2
$ACADIA Pharmaceuticals (ACAD.US)$ And where will the bottom be? Could it be a opportunity? Time will tell? Hehehe![]()
$ACADIA Pharmaceuticals (ACAD.US)$ Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effe...
1
6
No comment yet
Moni Moni Moo : may i know what mean 0% LTB?
Jaguar8 OP Moni Moni Moo : 0 short shares left to borrow
msaf79 : Thanks @Jaguar8
103732118 : Hi. PTIX.US will be delisted this Friday? After delist ed its shares cannot be traded in moomo? Thx.
Jaguar8 OP 103732118 : It needs to file appeal tomorrow. If there is no news of filing appeal tomorrow, then it will delist and may likely go to OTC
View more comments...